Lexicon Pharmaceuticals (LXRX) Non-Current Deffered Revenue (2010 - 2019)

Lexicon Pharmaceuticals (LXRX) has reported Non-Current Deffered Revenue for 10 consecutive years, with $24.3 million the latest figure, recorded in Q2 2019.

• In Q2 2019, Non-Current Deffered Revenue rose 33.38% year-over-year to $24.3 million; the TTM figure through Jun 2019 stood at $24.3 million (up 33.38% YoY), while the FY2018 annual figure was $23.7 million, down 5.03% from the prior year.
• Non-Current Deffered Revenue slipped to $24.3 million in Q2 2019 per LXRX's latest filing, from $24.6 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $109.2 million in Q4 2015 and bottomed at $11.7 million in Q1 2015.
• Historically, Non-Current Deffered Revenue has averaged $38.1 million across 5 years, with a median of $24.8 million in 2017.
• Annual changes were most pronounced in 2016 — Non-Current Deffered Revenue soared 777.17% — and 2017, when it tumbled 72.01%.
• Lexicon Pharmaceuticals' Non-Current Deffered Revenue stood at $109.2 million in 2015, then plunged by 55.17% to $48.9 million in 2016, then slumped by 49.11% to $24.9 million in 2017, then retreated by 5.03% to $23.7 million in 2018, then rose by 2.61% to $24.3 million in 2019.
• Business Quant data shows LXRX's Non-Current Deffered Revenue at $24.3 million in Q2 2019, $24.6 million in Q1 2019, and $23.7 million in Q4 2018.